Potential for a new coronary thrombolytic plateau

Journal of Thrombosis and Thrombolysis

Volumn 3, Issue 2, 1996, Pages 127-134

  Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Coronary thrombolysis; Fibrinolytics; Platelets; Thrombin; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ARGATROBAN; EFEGATRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LAMIFIBAN; LEPIRUDIN; PLASMINOGEN ACTIVATOR; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; DRUG POTENCY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 0029889533     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00132405     Document Type: Conference Paper

References (31)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
2. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
3. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615-1622.
4. Ohman E, Califf R, Topol E, et al. and the TAMI Study group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1982:781-791.
5. White HD, French JK, Hamer AW, et al. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy. J Am Coll Cardiol 1995;25:218-223.
6. Purvis J, Trouton T, Roberts et al. Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction. Am J Cardiol 1991;68:1570-1574.
7. Bleich S. Double bolus versus accelerate t-PA randomized trial (DOUBLE). Presented at the European Congress of Cardiology, Amsterdam, August 1995 .
8. Neuhaus KL, von Essen R, Vogt A, et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: Results of the German Recombinant Plasminogen Activator Study. J Am Coll Cardiol 1994;24:55-60.
9. Bode C, Smalling RW, Sen S, et al. and the RAPID Investigators. Recombinant Plasminogen Activator Angiographic Phase II International Dose Finding Study (RAPID). Patency analysis and mortality endpoints. Circulation 1993; 88(Suppl II):II562.
10. Weaver WD, Bode C, Burnett C, et al. for RAPID-2 Investigaors. Reteplase vs Alteplase Patency Investigation during Myocardial Infarction Trial (RAPID 2). J Am Coll Cardiol 1995;25:87A.
11. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329-336.
12. Keyt B, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674.
13. Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rats. Blood 1989;73:1842-1850.
14. Collen D, De Mol M, Demarsin E, De Cock F, Stassen JM. Isolation and conditioning of recombinant staphylokinase for use in man. Fibrinolysis 1993;7:242-247.
15. Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential. Blood 1994; 84:680-686.
16. Vanderschueren S, Barrios L, Kerdsinchai P, et al. for the STAR Trial Group. Circulation 1995;92:2044-2049.
17. Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992;79: 1213-1217.
18. Gardell SJ, Ramjit DR, Stabilito II, et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991;84:1-10.
19. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activation in an experimental rabbit model. Circulation 1995;91:1440-1544.
20. Ohman EM, Kleiman NS, Talley JD, et al. for the IMPACT-AMI Study Group. Simultaneous platelet glycoprotein IIb/ IIIa integrin blockade with acclerated tissue plasminogen activator in acute myocardial infarction. Circulation 1990(Suppl II):II564.
21. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. J Am Coll Cardiol 1993; 22:381-389.
22. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
23. Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. J Am Coll Cardiol 1995;75:7-13.
24. Lidon RM, Theroux P, Bonan R, Lesperance J, Maraganore J, Adelman B, Walters D. Hirulog as adjunctive therapy to streptokinase in acute myocardial infarction (abstract). J Am Coll Cardiol 1993;21(Suppl A):419A.
25. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-2139.
26. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hiruden for acute coronary syndromes. Circulation 1994;90:1631-1637.
27. Antman EM, for the TIMI 9 Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infaction (TIMI) 9A trial. Circulation 1994;90:1624-1630.
28. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeischaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-1642.
29. Stump DC, Califf RM, Topol EJ, et al. and the TAMI Study Group. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989;80:1222-1230.
30. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction N Engl J Med 1995;332:1418-1424.
31. Mark DB, Talley JD, Topol EJ, et al. for the EPIC Investigators. Economic assessment and quality of life outcomes and implications of platelet GPIIb/IIIa antibody therapy for coronary intervention. Ann Intern Med 1995, submitted.